Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S.

J Clin Oncol. 2019 Nov 1;37(31):2892-2898. doi: 10.1200/JCO.18.01931. Epub 2019 Sep 23.

PMID:
31545663
2.

Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience.

Soff GA, Mones J, Wilkins C, Devlin S, Haegler-Laube E, Wills J, Sarasohn DM, Juluru K, Singer M, Miao Y, Batista J, Mantha S.

Res Pract Thromb Haemost. 2019 May 24;3(3):349-356. doi: 10.1002/rth2.12215. eCollection 2019 Jul.

3.

Preventing Venous Thromboembolism in Patients with Cancer. Reply.

Khorana AA, Mones J, Soff GA.

N Engl J Med. 2019 May 30;380(22):2181. doi: 10.1056/NEJMc1904003. No abstract available.

PMID:
31141646
4.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
5.

Regulatory BC200 RNA in peripheral blood of patients with invasive breast cancer.

Iacoangeli A, Adzovic L, Chen EQ, Latif Cattie R, Soff GA, Tiedge H.

J Investig Med. 2018 Oct;66(7):1055-1063. doi: 10.1136/jim-2018-000717. Epub 2018 Jul 2.

6.

Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer.

Soff GA.

J Natl Compr Canc Netw. 2018 May;16(5S):670-673. doi: 10.6004/jnccn.2018.0041.

PMID:
29784753
7.

Predictive factors of fatal bleeding in acute promyelocytic leukemia.

Mantha S, Tallman MS, Devlin SM, Soff GA.

Thromb Res. 2018 Apr;164 Suppl 1:S98-S102. doi: 10.1016/j.thromres.2018.01.038. Review.

PMID:
29703492
8.

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.

Laube ES, Yu A, Gupta D, Miao Y, Samedy P, Wills J, Harnicar S, Soff GA, Mantha S.

Am J Cardiol. 2017 Jul 15;120(2):213-217. doi: 10.1016/j.amjcard.2017.04.009. Epub 2017 Apr 27.

9.

Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.

Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA.

J Thromb Thrombolysis. 2017 May;43(4):514-518. doi: 10.1007/s11239-017-1478-0.

10.

Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban.

Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA.

Am J Hematol. 2017 Jan;92(1):E9-E10. doi: 10.1002/ajh.24588. Epub 2016 Nov 22. No abstract available.

11.

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.

Mantha S, Laube E, Miao Y, Sarasohn DM, Parameswaran R, Stefanik S, Brar G, Samedy P, Wills J, Harnicar S, Soff GA.

J Thromb Thrombolysis. 2017 Feb;43(2):166-171. doi: 10.1007/s11239-016-1429-1.

12.

What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?

Mantha S, Tallman MS, Soff GA.

Curr Opin Hematol. 2016 Mar;23(2):121-6. doi: 10.1097/MOH.0000000000000221. Review.

PMID:
26760586
13.

Preoperative Chemoprophylaxis is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism.

Selby LV, Sovel M, Sjoberg DD, McSweeney M, Douglas D, Jones DR, Scardino PT, Soff GA, Fabbri N, Sepkowitz K, Strong VE, Sarkaria IS; MSKCC VTE Task Force.

J Am Coll Surg. 2016 Feb;222(2):129-37. doi: 10.1016/j.jamcollsurg.2015.11.011. Epub 2015 Dec 15.

14.

Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance.

Mantha S, Sarasohn D, Ma W, Devlin SM, Chi DS, Roche KL, Suidan RS, Woo K, Soff GA.

Am J Obstet Gynecol. 2015 Aug;213(2):208.e1-4. doi: 10.1016/j.ajog.2015.02.028. Epub 2015 Mar 2.

15.

Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling.

Giannarelli C, Alique M, Rodriguez DT, Yang DK, Jeong D, Calcagno C, Hutter R, Millon A, Kovacic JC, Weber T, Faries PL, Soff GA, Fayad ZA, Hajjar RJ, Fuster V, Badimon JJ.

Circulation. 2014 Oct 7;130(15):1274-86. doi: 10.1161/CIRCULATIONAHA.114.006614. Epub 2014 Aug 12. Erratum in: Circulation. 2016 Apr 19;133(16):e607.

16.

Clinical consequences of an indeterminate CT pulmonary angiogram in cancer patients.

Hayes SA, Soff GA, Zabor EC, Moskowitz CS, Liu CC, Ginsberg MS.

Clin Imaging. 2014 Sep-Oct;38(5):637-40. doi: 10.1016/j.clinimag.2014.04.015. Epub 2014 May 6.

17.

Commentary on "microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation".

Soff GA.

Transl Res. 2014 Feb;163(2):136-40. doi: 10.1016/j.trsl.2013.09.011. Epub 2013 Oct 1. No abstract available.

PMID:
24139900
18.

Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy.

Nathan H, Weiss MJ, Soff GA, Stempel M, Dematteo RP, Allen PJ, Kingham TP, Fong Y, Jarnagin WR, D'Angelica MI.

J Gastrointest Surg. 2014 Feb;18(2):295-302; discussion 302-3. doi: 10.1007/s11605-013-2383-2. Epub 2013 Oct 16.

PMID:
24129829
19.

Pathophysiology and management of thrombosis in cancer: 150 years of progress.

Soff GA.

J Thromb Thrombolysis. 2013 Apr;35(3):346-51. doi: 10.1007/s11239-013-0897-9. Review.

PMID:
23440574
20.

Combined factor V and factor VIII deficiency.

Soff GA.

Clin Adv Hematol Oncol. 2012 Jul;10(7):474-6. Review. No abstract available.

PMID:
22895292
21.

A new generation of oral direct anticoagulants.

Soff GA.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):569-74. doi: 10.1161/ATVBAHA.111.242834. Review.

PMID:
22345595
22.

Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.

Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O'Reilly EM.

Cancer. 2012 Jun 15;118(12):3053-61. doi: 10.1002/cncr.26600. Epub 2011 Oct 11.

23.

Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature.

Hyman DM, Soff GA, Kampel LJ.

Oncology. 2011;81(2):119-25. doi: 10.1159/000331705. Epub 2011 Oct 6. Review.

PMID:
21986538
24.

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Thorac Oncol. 2011 Jan;6(1):28-31. doi: 10.1097/JTO.0b013e3181fb4fe2.

25.

Thrombophilic-type placental pathologies and skeletal growth delay following maternal administration of angiostatin4.5 in mice.

Rutland CS, Atkinson SD, Mukhopadhyay M, Jiang K, Soff GA, Mayhew TM, Mitchell CA.

Biol Reprod. 2011 Mar;84(3):505-13. doi: 10.1095/biolreprod.110.083865. Epub 2010 Oct 27.

PMID:
20980690
26.
27.

The coagulation system and angiogenesis.

Sidhu G, Soff GA.

Cancer Treat Res. 2009;148:67-80. doi: 10.1007/978-0-387-79962-9_5. Review. No abstract available.

PMID:
19377919
28.

Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis.

Signaevsky M, Hobbs J, Doll J, Liu N, Soff GA.

Semin Thromb Hemost. 2008 Mar;34(2):161-9. doi: 10.1055/s-2008-1079256.

PMID:
18645921
29.

Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model.

Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, Crawford SE, Liu N, Signaevsky M, Soff GA.

Thromb Res. 2007;120 Suppl 2:S13-21. Erratum in: Thromb Res. 2008;123(1):187-90.

PMID:
18023707
30.

Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.

Wang H, Doll JA, Jiang K, Cundiff DL, Czarnecki JS, Wilson M, Ridge KM, Soff GA.

Cancer Res. 2006 Jul 15;66(14):7211-5.

31.

Angiostatin.

Doll JA, Soff GA.

Cancer Treat Res. 2005;126:175-204. Review. No abstract available.

PMID:
16209067
32.
33.

N-methylsansalvamide a peptide analogues. Potent new antitumor agents.

Liu S, Gu W, Lo D, Ding XZ, Ujiki M, Adrian TE, Soff GA, Silverman RB.

J Med Chem. 2005 May 19;48(10):3630-8.

PMID:
15887970
34.

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.

Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP Jr.

Contraception. 2004 Jul;70(1):3-10.

PMID:
15208046
35.

Cell surface-dependent generation of angiostatin4.5.

Wang H, Schultz R, Hong J, Cundiff DL, Jiang K, Soff GA.

Cancer Res. 2004 Jan 1;64(1):162-8.

36.

Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells.

Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA.

Cancer Res. 2003 Jul 15;63(14):4275-80.

38.

Angiostatin and angiostatin-related proteins.

Soff GA.

Cancer Metastasis Rev. 2000;19(1-2):97-107. Review.

PMID:
11191071
39.

Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1.

Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T, Jain RK.

Nat Med. 1999 Oct;5(10):1203-8.

PMID:
10502827
40.

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA.

Biochem J. 1999 May 15;340 ( Pt 1):77-84.

41.

Nitric oxide--cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases.

Lincoln TM, Dey NB, Boerth NJ, Cornwell TL, Soff GA.

Acta Physiol Scand. 1998 Dec;164(4):507-15.

PMID:
9887973
42.

Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.

Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR.

Cancer Res. 1998 Dec 15;58(24):5686-9.

43.

Multiple forms of angiostatin induce apoptosis in endothelial cells.

Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS.

Blood. 1998 Dec 15;92(12):4730-41.

PMID:
9845539
44.

Combined effects of angiostatin and ionizing radiation in antitumour therapy.

Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR.

Nature. 1998 Jul 16;394(6690):287-91.

PMID:
9685160
45.

Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.

Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS.

Cancer Res. 1997 Dec 1;57(23):5277-80.

47.

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10868-72.

48.

Activated-protein-C resistance in cancer patients.

Green D, Maliekel K, Sushko E, Akhtar R, Soff GA.

Haemostasis. 1997 May-Jun;27(3):112-8.

PMID:
9306127
49.

Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Kwaan HC, Soff GA.

Semin Hematol. 1997 Apr;34(2):159-66. Review. No abstract available.

PMID:
9109218
50.

Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA.

Cancer Res. 1996 Nov 1;56(21):4887-90.

Supplemental Content

Support Center